Cuộc họp công bố kết quả kinh doanh Quý 3/2026 của PTC Therapeutics (PTCT): Suffiance thúc đẩy nâng dự báo
Doanh thu quý 3/2026 của PTC Therapeutics đạt 358 triệu USD, trong đó Suffiance đóng góp 182 triệu USD. Công ty đã nâng định hướng kinh doanh cả năm và công bố chi tiết các kế hoạch đối với ST920.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).